Dabigatran versus Warfarin in Patients with Atrial Fibrillation
Stuart J. Connolly(Population Health Research Institute), Lars Wallentin(Uppsala University), Rafael Díaz(Estudios Clínicos Latinoamérica), Salim Yusuf(Population Health Research Institute), Jun Zhu(Population Health Research Institute), Michael D. Ezekowitz(Lankenau Institute for Medical Research), Marco Alings(Utrecht University), Harald Darius(Vivantes Klinikum), Jeanne Varrone(Boehringer Ingelheim (United States)), Denis Xavier(McMaster University), Ellison Themeles(Population Health Research Institute), Jonas Oldgren(Uppsala University), John W. Eikelboom(Population Health Research Institute), Hans‐Christoph Diener(Vivantes Klinikum), Susan Wang(Boehringer Ingelheim (United States)), Campbell Joyner(Sunnybrook Health Science Centre), Janice Pogue(McMaster University), Amit Parekh(Lankenau Institute for Medical Research), Paul Reilly(Boehringer Ingelheim (United States)), Basil S. Lewis(Technion – Israel Institute of Technology)
Cited by 11,189
Related Papers
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
Guidelines for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack
|Stroke|2014|5.2k
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k